secwatch.observer — SEC 8-K summary
======================================

Issuer:     Stoke Therapeutics, Inc. (STOK)
CIK:        0001623526
Form:       8-K
Filed at:   2024-09-10T23:59:59+00:00
Accession:  0001193125-24-216632
Event type: litigation
Sentiment:  neutral
Materiality: 0.55
Item codes: 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Stoke Therapeutics settles shareholder derivative lawsuit; $590K in fees, governance reforms
--------------------------------------------------------------------------------

- Mootness fee of $175,000 paid to resolve certain director compensation claims; company denies wrongdoing.
- Proposed settlement filed Aug 20, 2024; includes corporate governance reforms and up to $415,000 in attorney fees.
- Reforms cap director compensation at 65th percentile of peer group and require value-based equity grants and annual consultant review.
- Court approval required; settlement hearing scheduled for Oct 28, 2024.
- Company agrees to maintain reforms for five years.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1623526/000119312524216632/0001193125-24-216632-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1623526/000119312524216632/d836605d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-24-216632

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer